Cosentyx and Post inflammatory pigmentation change - a phase IV clinical study of FDA data

Summary:

Post inflammatory pigmentation change is reported as a side effect among people who take Cosentyx (secukinumab), especially for people who are male, 40-49 old, have been taking the drug for 1 - 6 months also take Methotrexate, and have Psoriasis.

The phase IV clinical study analyzes which people have Post inflammatory pigmentation change when taking Cosentyx. It is created by eHealthMe based on reports of 187,010 people who have side effects when taking Cosentyx from the FDA, and is updated regularly.

What is Cosentyx?

Cosentyx has active ingredients of secukinumab. It is often used in psoriatic arthritis. eHealthMe is studying from 187,247 Cosentyx users. Check the latest studies of Cosentyx.

What is Post inflammatory pigmentation change?

Post inflammatory pigmentation change is found to be associated with 70 drugs and 132 conditions by eHealthMe. Check the latest studies of Post inflammatory pigmentation change.

On Aug, 11, 2026

187,010 people reported to have side effects when taking Cosentyx.
Among them, 37 people (0.02%) have Post inflammatory pigmentation change.

Could Cosentyx cause Post inflammatory pigmentation change?

Among these 37 people:

How long have people been on Cosentyx when they have Post inflammatory pigmentation change? *

What is the gender of people who have Post inflammatory pigmentation change when taking Cosentyx? *

female: 37.84 %
male: 62.16 %

What is the age of people who have Post inflammatory pigmentation change when taking Cosentyx? *

What are other drugs people take besides Cosentyx? *

What are other side effects people have besides Post inflammatory pigmentation change? *

Rashes (redness): 18 people, 48.65%
Psoriasis (immune-mediated disease that affects the skin): 18 people, 48.65%
Itching: 14 people, 37.84%
Skin Exfoliation (removal of the oldest dead skin cells): 13 people, 35.14%
Drug Ineffective: 9 people, 24.32%
Skin Plaque (red, scaly patches to appear on the skin): 7 people, 18.92%
Papule: 6 people, 16.22%
Lichenification (thickening and hardening of the skin): 5 people, 13.51%
Arthropathy: 5 people, 13.51%
Joint Pain: 5 people, 13.51%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 31 people, 83.78%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 2 people, 5.41%
Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 2.70%
Hidradenitis (chronic disease of a type of sweat gland): 1 person, 2.70%

* Approximation only. Some reports may have incomplete information.

Do you take Cosentyx and have Post inflammatory pigmentation change?

- Check whether Post inflammatory pigmentation change is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cosentyx:

Cosentyx (187,247 reports)

Browse all side effects of Cosentyx:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Post inflammatory pigmentation change:

Post inflammatory pigmentation change (70 drugs)

Browse all the conditions that are associated with Post inflammatory pigmentation change:

Post inflammatory pigmentation change (132 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on secukinumab (the active ingredients of Cosentyx) and Cosentyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.